Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Guided Therapeutics (GTHP) over the last 11 years, with Q3 2025 value amounting to -$257000.0.

  • Guided Therapeutics' Non Operating Income fell 17634.41% to -$257000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$213000.0, marking a year-over-year decrease of 96500.0%. This contributed to the annual value of -$309000.0 for FY2024, which is 89230.77% down from last year.
  • Per Guided Therapeutics' latest filing, its Non Operating Income stood at -$257000.0 for Q3 2025, which was down 17634.41% from $64000.0 recorded in Q2 2025.
  • Guided Therapeutics' Non Operating Income's 5-year high stood at $555000.0 during Q3 2021, with a 5-year trough of -$859000.0 in Q4 2022.
  • Its 5-year average for Non Operating Income is -$52421.1, with a median of -$52000.0 in 2023.
  • Per our database at Business Quant, Guided Therapeutics' Non Operating Income tumbled by 944444.44% in 2022 and then skyrocketed by 32790.7% in 2025.
  • Guided Therapeutics' Non Operating Income (Quarter) stood at -$9000.0 in 2021, then plummeted by 9444.44% to -$859000.0 in 2022, then skyrocketed by 119.79% to $170000.0 in 2023, then plummeted by 169.41% to -$118000.0 in 2024, then plummeted by 117.8% to -$257000.0 in 2025.
  • Its Non Operating Income stands at -$257000.0 for Q3 2025, versus $64000.0 for Q2 2025 and $98000.0 for Q1 2025.